Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.

  • Voyager Therapeutics' Net Income towards Common Stockholders fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
  • Latest data reveals that Voyager Therapeutics reported Net Income towards Common Stockholders of -$27.9 million as of Q3 2025, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Net Income towards Common Stockholders peaked at $124.0 million during Q1 2023, and registered a low of -$34.5 million during Q4 2024.
  • Its 5-year average for Net Income towards Common Stockholders is -$7.6 million, with a median of -$22.2 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 51383.78% in 2022, then surged by 68184.72% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $5.7 million in 2021, then crashed by 513.84% to -$23.6 million in 2022, then soared by 338.7% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then grew by 19.12% to -$27.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$27.9 million for Q3 2025, versus -$33.4 million for Q2 2025 and -$31.0 million for Q1 2025.